PepGen Appoints Laurie Keating as Chair of Board of Directors
January 19 2022 - 8:00AM
PepGen, Inc., a company advancing next-generation
oligonucleotide therapies for neuromuscular and neurologic
diseases, today announced that it has appointed Laurie Keating as
Chair of the company’s Board of Directors.
“We are very pleased that Laurie has agreed to join as Chair of
our Board of Directors – she is a seasoned executive and Board
member who has been a key member of the executive teams of two
Boston biotechs that have transitioned from preclinical to
successful commercial companies. We look forward to her strategic
contributions and guidance as we continue to grow and build PepGen
into a leading oligonucleotide therapies company focused on serious
genetic disorders,” said James McArthur, Ph.D., President and Chief
Executive Officer of PepGen.
Dr. McArthur continued, “Laurie replaces Ramin Farzaneh-Far,
M.D., who served as PepGen’s Board Chair from November 2020 and
will continue in his current role as acting Chief Medical Officer.
We are very grateful to Ramin for his critical service in advancing
the company, and for his support during our Series A and B
fundraising rounds.”
In addition to her role on the PepGen Board of Directors, Laurie
also serves as a Director of Immuneering Corp (Nasdaq:IMRX) and
Imago Biosciences (Nasdaq:IMGO), and has served for more than ten
years on the Board of MassBio. Laurie previously served as the
Executive Vice President, General Counsel and Corporate Secretary
of Alnylam Pharmaceuticals. In this role she led global government
affairs, legal, IP, litigation and compliance, and advised the
Board on financing and strategic collaborations, governance, and
corporate strategy. Prior to Alnylam, she served as SVP, General
Counsel and Corporate Secretary of Millennium Pharmaceuticals, a
commercial stage company that was later acquired by Takeda. At
Millennium, Laurie led the global Legal,
Intellectual Property, Corporate Quality and Compliance
groups. Prior to Millennium, Laurie was founding CEO and a
director of Hydra Biosciences. Her contributions and executive
leadership at public high technology companies earlier in her
career led to her being named one of the 45 most influential
in-house lawyers in the U.S. under the age of 45. Laurie earned her
bachelor’s degree in Economics from the University of California at
Berkeley, and her JD from the University of California, Hastings
College of the Law.
“I am thrilled to be joining PepGen as the new Chair of the
Board of Directors. I look forward to guiding the company’s
development and supporting the leadership team as they seek to
transform the lives of patients with innovative new treatment
options for severe neuromuscular and neurologic diseases,” Keating
said.
About PepGen PepGen, Inc. is a
biotechnology company advancing next-generation oligonucleotide
therapies for neuromuscular and neurologic diseases. PepGen’s
proprietary Enhanced Delivery Oligonucleotides (EDOs) are designed
to target the underlying causes of rare diseases safely and
effectively such as Duchenne muscular dystrophy (DMD) and myotonic
dystrophy type 1 (DM1). In preclinical studies, PepGen’s enhanced
delivery peptides demonstrated success in cell penetration and
delivery of therapeutic candidates to multiple tissue types,
including cardiac tissue. PepGen was founded by leading neurology
researchers in Oxford, UK and is backed by a strong syndicate of
investors including RA Capital Management, Oxford Science
Enterprises, and others. The company is headquartered in Boston,
Mass. For more information, visit www.pepgen.com or
follow PepGen on Twitter and LinkedIn.
Media Contact Gwendolyn
Schanker LifeSci
Communications gschanker@lifescicomms.com
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024